TIGIT/CD226 Axis Regulates Anti-Tumor Immunity

Tumors escape immune surveillance by inducing various immunosuppressive pathways, including the activation of inhibitory receptors on tumor-infiltrating T cells. While monoclonal antibodies (mAbs) blocking programmed cell death 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T lymphocyte-...

Full description

Bibliographic Details
Published in:	Pharmaceuticals
Main Authors:	Jinah Yeo, Minkyung Ko, Dong-Hee Lee, Yoon Park, Hyung-seung Jin
Format:	Article
Language:	English
Published:	MDPI AG 2021-02-01
Subjects:	cancer immunotherapy immune checkpoint blockade CD226 TIGIT PVR
Online Access:	https://www.mdpi.com/1424-8247/14/3/200

Similar Items

Expression of the immune checkpoint molecules CD226 and TIGIT in preeclampsia patients
by: Cui Li, et al.
Published: (2024-02-01)

Examination of the TIGIT, CD226, CD112, and CD155 Immune Checkpoint Molecules in Peripheral Blood Mononuclear Cells in Women Diagnosed with Early-Onset Preeclampsia
by: Laszlo Szereday, et al.
Published: (2021-11-01)

Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer
by: Hauke Stamm, et al.
Published: (2019-12-01)

Expression of the Inhibitory Receptor TIGIT Is Up-Regulated Specifically on NK Cells With CD226 Activating Receptor From HIV-Infected Individuals
by: Xiaowan Yin, et al.
Published: (2018-10-01)

Anti-TIGIT therapies: a review of preclinical and clinical efficacy and mechanisms
by: Erin C. Sundstrom, et al.
Published: (2025-07-01)

Overexpression of TIGIT in NK and T Cells Contributes to Tumor Immune Escape in Myelodysplastic Syndromes
by: Fanqiao Meng, et al.
Published: (2020-08-01)

Expression of TIGIT in splenic and circulatory T cells from mice acutely infected with Toxoplasma gondii
by: Wang Shuai, et al.
Published: (2021-01-01)

CD155-TIGIT/CD96/CD226 immune checkpoint axis interacting with tumor-infiltrating lymphocytes to exhibit diverse prognostic effects on breast cancer: a cohort study
by: Xin Ou, et al.
Published: (2025-10-01)

Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells
by: Xiu-Man Zhou, et al.
Published: (2018-11-01)

Studying TIGIT activity against tumors through the generation of knockout mice
by: Ahmed Rishiq, et al.
Published: (2023-12-01)

Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy
by: Xiuman Zhou, et al.
Published: (2021-05-01)

Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR
by: Xiuman Zhou, et al.
Published: (2020-09-01)

Increased TIGIT expression correlates with impaired NK cell function in diffuse large B-cell lymphoma
by: Hui Lu, et al.
Published: (2025-03-01)

Pan-cancer analysis identifies CD155 as a promising target for CAR-T cell therapy
by: Xiaohong Liu, et al.
Published: (2025-06-01)

Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma
by: Sophie Rovers, et al.
Published: (2022-03-01)

Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development
by: Anand Rotte, et al.
Published: (2021-09-01)

The immune checkpoint TIGIT/CD155 promotes the exhaustion of CD8 + T cells in TNBC through glucose metabolic reprogramming mediated by PI3K/AKT/mTOR signaling
by: Mingyao Huang, et al.
Published: (2024-01-01)

Characterization of ASP8374, a fully-human, antagonistic anti-TIGIT monoclonal antibody
by: Kenna Shirasuna, et al.
Published: (2021-01-01)

PVR (CD155) Expression as a Potential Prognostic Marker in Multiple Myeloma
by: Byung-Hyun Lee, et al.
Published: (2022-05-01)

The regulatory effects and applications of TIGIT/CD155 on the tumor microenvironment in HCC
by: Wenting Li, et al.
Published: (2025-10-01)

TIGIT/CD47 dual high expression predicts prognosis and is associated with immunotherapy response in lung squamous cell carcinoma
by: Yue Peng, et al.
Published: (2022-07-01)

Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer
by: Marina Martinez, et al.
Published: (2021-01-01)

TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer
by: Zhouhong Ge, et al.
Published: (2021-07-01)

Corrigendum: Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation
by: Jin-Hwan Han, et al.
Published: (2020-11-01)

Serum Level of Soluble CD226 Receptor in Healthy Individuals is Highly Variable and Associated with Age
by: Anna Hogendorf, et al.
Published: (2019-03-01)

Peptide-based PET imaging agent of tumor TIGIT expression
by: Dinghu Weng, et al.
Published: (2023-05-01)

TIGIT Induces (CD3+) T Cell Dysfunction in Colorectal Cancer by Inhibiting Glucose Metabolism
by: Qi Shao, et al.
Published: (2021-09-01)

Targeting TIGIT for cancer immunotherapy: recent advances and future directions
by: Peng Zhang, et al.
Published: (2024-01-01)

Tiragolumab and TIGIT: pioneering the next era of cancer immunotherapy
by: Kosar Ghasemi, et al.
Published: (2025-06-01)

Identification of Epinastine as CD96/PVR inhibitor for cancer immunotherapy
by: Xiangrui Zhang, et al.
Published: (2025-01-01)

CD226: An Emerging Role in Immunologic Diseases
by: Zhiyi Huang, et al.
Published: (2020-07-01)

GD2-CAR NK-92 cell activity against neuroblastoma cells is insusceptible to TIGIT knockout
by: Wiebke Jünemann, et al.
Published: (2025-05-01)

Gene Expression of CD226 and Its Serum Levels in Patients With Multiple Sclerosis
by: Fereshteh Alsahebfosoul, et al.
Published: (2018-08-01)

iPSC-derived NK cells engineered with CD226 effectively control acute myeloid leukemia
by: Runze Cai, et al.
Published: (2025-07-01)

Blocking CD226 Promotes Allogeneic Transplant Immune Tolerance and Improves Skin Graft Survival by Increasing the Frequency of Regulatory T Cells in a Murine Model
by: Tian Liu, et al.
Published: (2018-03-01)

Association Study of CD226 and CD247 Genes Single Nucleotide Polymorphisms in Iranian Patients with Systemic Sclerosis
by: Fatemeh Abbasi, et al.
Published: (2017-12-01)

Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor
by: Jingjing Zhao, et al.
Published: (2023-12-01)

Dual targeting of TIGIT and VISTA in non-small-cell lung cancer immunotherapy
by: Alaa A. A. Aljabali, et al.
Published: (2025-08-01)

Expression of CD39 is associated with T cell exhaustion in ovarian cancer and its blockade reverts T cell dysfunction
by: Marius Witt, et al.
Published: (2024-12-01)

Expression of the immune checkpoint receptor TIGIT in Hodgkin’s lymphoma
by: Wenchao Li, et al.
Published: (2018-12-01)